Cytox Announces Participation In Insight Alzheimer’s Study
13 October 2015 Participation will aid comparison of SNP genotyping with biomarker status Cytox Ltd,…
read moreCytox is developing a diagnostic test and therapeutic cures for Alzheimer’s Disease which is estimated to affect 15 million people worldwide. The company is a university spin-out based on groundbreaking academic research into the role of the cell cycle in neuro-degenerative diseases.
Status current
Associated Fund
Advantage Growth Fund,
UK Innovation & Science Seed Fund
Sector Medical / Biotechnology
Website www.cytoxgroup.com/
13 October 2015 Participation will aid comparison of SNP genotyping with biomarker status Cytox Ltd,…
read moreCollaboration Will Contribute To Further Refinement Of Diagnostic SNPs For Alzheimer’s Disease 1 June 2015:…
read moreManchester & Oxford, UK, 25 January 2013 – Cytox Limited, developer of a unique blood…
read moreCytox, which has offices in Manchester and Oxford, has a mission to transform how...
read moreUpdate your browser to view this website correctly.Update my browser now